Gilead Sciences (GILD)
Gilead Sciences' (GILD) Remdesivir Sparks Market Hope With Trial Success
Gilead Sciences' (GILD) Remdesivir Sparks Market Hope With Trial Success
Gilead's COVID-19 treatment shows efficacy in Phase 3 trial, NIAID study
April 29, 2020
How to Survive the Economic Fallout from COVID-19
How to Survive the Economic Fallout from COVID-19
The bull market and economic expansion are over. Here's what to do now.
March 26, 2020
10 Value Stocks to Buy for 2018 and Beyond
10 Value Stocks to Buy for 2018 and Beyond
The stock market was unkind to Warren Buffett disciples in 2017.
January 12, 2018
5 Undervalued Stocks With Free Cash Flow to Burn
5 Undervalued Stocks With Free Cash Flow to Burn
Look beyond the P/E. These five firms are inexpensive based on free cash flow.
September 22, 2017
Why I'm Hanging On to a Loser
Why I'm Hanging On to a Loser
Gilead is way down from when I bought it, but it is flush with cash and has dozens of promising medications in its pipeline.
August 24, 2017
Subscribe to Kiplinger's Personal Finance
Be a smarter, better informed investor.
This Stumbling Biotech Stock Still Has a Lot of Promise
This Stumbling Biotech Stock Still Has a Lot of Promise
Gilead Sciences' robust product pipeline should turn things around.
January 3, 2017
3 Bargain Stocks to Beat the Market
3 Bargain Stocks to Beat the Market
The Value Line Investment Survey sees a strong year ahead for these picks.
June 2, 2015
Promising Bargains in Biotech Stocks
Promising Bargains in Biotech Stocks
What I like about BioDelivery Sciences is not so much that there are many ways to win as that there are almost no ways to lose.
October 6, 2014